Clinical Trials Research Center, Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre, 5850/5980 University Avenue, Halifax, NS, B3K 6R8, Canada.
Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22.
With the emergence of multiple meningococcal serogroups in different geographic areas, broad vaccine protection from infancy is desirable. One hundred and seventy-five infants received either two doses of a meningococcal quadrivalent (A, C, W-135, Y) conjugate vaccine (MenACWY-CRM) at 6 and 12 months, one dose of MenACWY-CRM at 12 months, or MenC at 12 months and MenACWY-CRM at 18 months. Bactericidal antibody titers using human complement were measured before and 1 month after each dose. Injection-site reactions were reported by 22-45% of participants following MenACWY-CRM given at 6 or 12 months. Similar proportions of subjects had injection-site reactions following two doses of MenACWY-CRM (32-41%) or one dose of MenC (26-44%). The incidence of systemic adverse events was comparable between groups. After two doses of MenACWY-CRM, the percentages of participants reporting hSBA titers >or=8 were 100% for C, W-135, and Y, and 84% for A. Serogroup C titers were more than 10-fold higher after two doses of MenACWY-CRM than after one dose of MenC or MenACWY-CRM at 12 months. Serogroup C titers were comparable following a single dose of MenACWY-CRM or MenC at 12 months. MenACWY-CRM is well tolerated and immunogenic given at 12 months, or two doses at 6 and 12 months of age.
随着不同地理区域中出现多种脑膜炎奈瑟菌血清群，从婴儿期开始广泛的疫苗保护是理想的。175 名婴儿分别在 6 个月和 12 个月时接受了两剂脑膜炎球菌四价（A、C、W-135、Y）结合疫苗（MenACWY-CRM）、12 个月时接受一剂 MenACWY-CRM、或 12 个月时接种 MenC 和 18 个月时接种 MenACWY-CRM。在每次接种前和接种后 1 个月，用人补体测量杀菌抗体滴度。在 6 个月或 12 个月时接种 MenACWY-CRM 后，22%-45%的参与者报告出现注射部位反应。接种两剂 MenACWY-CRM（32%-41%）或一剂 MenC（26%-44%）的受试者有相似比例出现注射部位反应。各组之间的全身不良事件发生率相当。接种两剂 MenACWY-CRM 后，报告 hSBA 滴度≥8 的参与者百分比为 C、W-135 和 Y 组为 100%，A 组为 84%。与 12 个月时接种一剂 MenC 或 MenACWY-CRM 相比，接种两剂 MenACWY-CRM 后血清群 C 滴度提高了 10 多倍。在 12 个月时接种一剂 MenACWY-CRM 或 MenC 后，血清群 C 滴度相当。在 12 个月时接种一剂或两剂 MenACWY-CRM 时，MenACWY-CRM 具有良好的耐受性和免疫原性。
